Cargando…

Should we stop prescribing metoclopramide as a prokinetic drug in critically ill patients?

Regulatory agencies in North America and Europe recently re-evaluated the safety of metoclopramide. This re-evaluation resulted in recommendations and restrictions in order to minimise the risk of neurological and other adverse reactions associated with the use of metoclopramide. In the ICU, off-lab...

Descripción completa

Detalles Bibliográficos
Autores principales:	van der Meer, Y Gert, Venhuizen, Willem A, Heyland, Daren K, van Zanten, Arthur RH
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Viewpoint
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4331179/ https://www.ncbi.nlm.nih.gov/pubmed/25672546 http://dx.doi.org/10.1186/s13054-014-0502-4

Ejemplares similares

Should We Prescribe More Protein to Critically Ill Patients?
por: Heyland, Daren K., et al.
Publicado: (2018)

Do we need new prokinetics to reduce enteral feeding intolerance during critical illness?
por: van Zanten, Arthur Raymond Hubert
Publicado: (2016)

Does artificial nutrition improve outcome of critical illness? An alternative viewpoint!
por: Heyland, Daren K, et al.
Publicado: (2013)

Metoclopramide as a prokinetic agent for diabetic gastroparesis: revisiting the risk of Parkinsonism
por: Lai, Chien-Hsu, et al.
Publicado: (2019)

Should we stop using the determination of central venous pressure as a way to estimate cardiac preload?
por: Cerón Arias, Johann Smith, et al.
Publicado: (2012)

For the love of all that is holy, stop prescribing sodium valproate and carbamazepine together
por: Jawaid, Wajid
Publicado: (2023)

Should We Use an Orphan Graft?
por: Baskıran, A., et al.
Publicado: (2017)

Enteral glutamine supplementation in critically ill patients: a systematic review and meta-analysis
por: van Zanten, Arthur R. H., et al.
Publicado: (2015)

Does the evidence show that prokinetic agents are effective in healing esophagitis and improving symptoms of GERD?
por: Looijer-van Langen, Mirjam, et al.
Publicado: (2007)

Undergraduate medical education; how far should we go?
por: Benamer, Hani TS
Publicado: (2007)

Atherosclerotic renal artery stenosis: how should we do?
por: Jiang, Ying, et al.
Publicado: (2021)

How should we fund end-of-life care in the US?
por: Arapakis, Karolos, et al.
Publicado: (2022)

Guinea worm eradication: Progress and challenges— should we beware of the dog?
por: Molyneux, David, et al.
Publicado: (2017)

The care of infants with rapid weight gain: Should we be doing more?
por: Fangupo, Louise, et al.
Publicado: (2022)

Why Reducing Low-Value Care Fails to Bend the Cost Curve, and Why We Should Do it Anyway
por: Kroon, Daniëlle, et al.
Publicado: (2023)

How much diagnostic safety can we afford, and how should we decide? A health economics perspective
por: Newman-Toker, David E, et al.
Publicado: (2013)

COVID-19: What we’ve done well and what we could or should have done better—the 4 Ps
por: Vincent, Jean-Louis, et al.
Publicado: (2021)

Development of Diagnostics for Chagas Disease: Where Should We Put Our Limited Resources?
por: Picado, Albert, et al.
Publicado: (2017)

Control of Urban Zika Vectors: Should We Return to the Successful PAHO/WHO Strategy?
por: Reiter, Paul
Publicado: (2016)

How should we think about the unprecedented weight loss efficacy of incretin-mimetic drugs?
por: Gou, Yang, et al.
Publicado: (2023)

Erythropoietin in the critically ill: do we ask the right questions?
por: McCook, Oscar, et al.
Publicado: (2012)

Should we measure the central venous pressure to guide fluid management? Ten answers to 10 questions
por: De Backer, Daniel, et al.
Publicado: (2018)

Evaluation of low gradient severe aortic stenosis: should we change our outlook in the analysis of clinical data?
por: Corazza, Ivan, et al.
Publicado: (2021)

Should we stop methotrexate or not for vaccination?
por: Durez, Patrick, et al.
Publicado: (2023)

Why we should all be more careful in drawing conclusions about how COVID-19 is changing drug markets
por: Giommoni, Luca
Publicado: (2020)

The impact of COVID-19 pandemic on AIDS-related mycoses and fungal neglected tropical diseases: Why should we worry?
por: Nargesi, Sanaz, et al.
Publicado: (2021)

The Prokinetic Face of Ghrelin
por: Sallam, Hanaa S., et al.
Publicado: (2010)

Editorial: Personalized nutrition therapy in critical illness and convalescence: moving beyond one-size-fits-all to phenotyping and endotyping
por: van Zanten, Arthur R.H.
Publicado: (2023)

A call to action—stopping antimicrobial resistance
por: Eisinger, Robert W, et al.
Publicado: (2023)

Glutamine supplementation in the critically ill: friend or foe?
por: Oudemans-van Straaten, Heleen M, et al.
Publicado: (2014)

The effect of a physician-targeted intervention on metoclopramide prescribing practice
por: Yang, Yu-Xiao, et al.
Publicado: (2011)

When there is a pandemic there is no time to waste: should we have hydroxychloroquine in our armoury against COVID-19 infected patients?
por: Bogdanos, Dimitrios P., et al.
Publicado: (2020)

Mandatory universal masking is the key to stop COVID-19
por: Lin, Timothy PH, et al.
Publicado: (2020)

Mandatory certification for clozapine prescribing
por: Cohen, Dan, et al.
Publicado: (2020)

Erythromycin or metoclopramide for feed intolerance in the critically ill
por: Nguyen, N, et al.
Publicado: (2006)

Rikkunshito as a Therapeautic Agent for Functional Dyspepsia and its Prokinetic and Non-Prokinetic Effects
por: Inokuchi, Kazumi, et al.
Publicado: (2021)

The P Value Line Dance: When Does the Music Stop?
por: Bendtsen, Marcus
Publicado: (2020)

Prescribing generics: All in a name
por: Roy, Vandana, et al.
Publicado: (2018)

Stopping female feticide in India: the failure and unintended consequence of ultrasound restriction
por: Tabaie, Sheida
Publicado: (2017)

Prokinetic agents in critical care
por: Doherty, Warren L, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_sgd8j0ckeinfcskjkon266eqcd